Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | FABP7 | O15540 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438578 | 1.00 | FABP5 (0.34) | FABP5F10FABP7CASP3KMT2A | |
| SCHEMBL5485683 | 0.74 | KMT2A (0.46) | FABP5F10FABP7KMT2APOLB | |
| SCHEMBL119453 | 0.68 | FABP5 (0.52) | FABP5F10FABP7CASP3KMT2A | |
| SCHEMBL25807850 | 0.68 | KMT2A (0.44) | FABP5F10FABP7CASP3KMT2A | |
| SCHEMBL30491856 | 0.68 | KMT2A (0.44) | FABP5F10FABP7CASP3KMT2A | |
| SCHEMBL4709998 | 0.68 | FABP5 (0.49) | FABP5F10FABP7CASP3KMT2A | |
| SCHEMBL22397770 | 0.68 | POLB (0.52) | FABP5FABP7KMT2APOLBEPHX2 | |
| SCHEMBL13327274 | 0.68 | POLB (0.52) | FABP5FABP7KMT2APOLBEPHX2 | |
| SCHEMBL6855032 | 0.67 | KMT2A (0.46) | FABP5F10FABP7CASP3KMT2A | |
| SCHEMBL7926629 | 0.67 | KMT2A (0.46) | FABP5F10FABP7CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | FABP5 2373/4885F10 3554/4885FABP7 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.